Abstract
Tumors of the central nervous system are the third most common type of childhood cancers. Brain tumors occur in children and adults; however pediatric patients require a different treatment process. Thirteen drugs similar to mechlorethamine are analyzed in this study. These drugs possess molecular properties enabling substantial and successful access to tumors of the central nervous system. All drugs exhibit zero violations of the Rule of 5, which indicate favorable bioavailability. Ranges in Log P, formula weight, and polar surface area for these drugs are: 1.554 to 3.52, 156.06 to 460.45, and 3.238 Angstroms2 to 45.471 Angstroms2, respectively. Hierarchical cluster analysis determined that agents 7 and 12 are most similar to the parent compound mechlorethamine. The mean values of Log P, formula weight, polar surface area, and molecular volume are 2.25, 268.51, 16.57 Angstroms2, and 227.01 Angstroms3, respectively. Principal component analysis indicates that agents 7 and 12 are most similar to mechlorethamine and multiple regression analysis of molecular properties produced a model to enable the design of similar alkylating agents. Values of Log (Cbrain/Cblood) indicate these agents will have very high permeation into the central nervous system.
Keywords: Brain, glioma and astrocytomas, mechlorethamine, spinal cord, tumors.
Central Nervous System Agents in Medicinal Chemistry
Title:Mechlorethamine based Drug Structures for Intervention of Central Nervous System Tumors
Volume: 13 Issue: 2
Author(s): Ronald Bartzatt
Affiliation:
Keywords: Brain, glioma and astrocytomas, mechlorethamine, spinal cord, tumors.
Abstract: Tumors of the central nervous system are the third most common type of childhood cancers. Brain tumors occur in children and adults; however pediatric patients require a different treatment process. Thirteen drugs similar to mechlorethamine are analyzed in this study. These drugs possess molecular properties enabling substantial and successful access to tumors of the central nervous system. All drugs exhibit zero violations of the Rule of 5, which indicate favorable bioavailability. Ranges in Log P, formula weight, and polar surface area for these drugs are: 1.554 to 3.52, 156.06 to 460.45, and 3.238 Angstroms2 to 45.471 Angstroms2, respectively. Hierarchical cluster analysis determined that agents 7 and 12 are most similar to the parent compound mechlorethamine. The mean values of Log P, formula weight, polar surface area, and molecular volume are 2.25, 268.51, 16.57 Angstroms2, and 227.01 Angstroms3, respectively. Principal component analysis indicates that agents 7 and 12 are most similar to mechlorethamine and multiple regression analysis of molecular properties produced a model to enable the design of similar alkylating agents. Values of Log (Cbrain/Cblood) indicate these agents will have very high permeation into the central nervous system.
Export Options
About this article
Cite this article as:
Bartzatt Ronald, Mechlorethamine based Drug Structures for Intervention of Central Nervous System Tumors, Central Nervous System Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/18715249113139990013
DOI https://dx.doi.org/10.2174/18715249113139990013 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Detecting Sudden Gains during Treatment of Major Depressive Disorder: Cautions from a Monte Carlo Analysis
Current Psychiatry Reviews Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma
Current Drug Targets Recent Advances in Psoriasis Therapy: Trends and Future Prospects
Current Drug Targets Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets PCR Detection and Sequencing of <i>Trichomonas vaginalis</i> in Women with Suspected Vaginitis in Southwestern Iran
Infectious Disorders - Drug Targets Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
Combinatorial Chemistry & High Throughput Screening Pharmacogenomics: Dont Forget the Children
Current Pharmacogenomics and Personalized Medicine The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology
Current Cancer Drug Targets